Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?

Drug Discovery Today

Volumn 19, Issue 3, 2014, Pages 312-319

  Verron, E ^a   Bouler, J M ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; GERANYLTRANSFERASE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PYROPHOSPHATE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TILUDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

BONE DISEASE; BONE MINERAL; BONE REMODELING; CALCIFICATION; CANCER THERAPY; CELL SURVIVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FRAGILITY FRACTURE; HORMONAL THERAPY; HUMAN; JAW OSTEONECROSIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; REVIEW; ANIMAL; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE NEOPLASMS; CHEMICALLY INDUCED; FRACTURES, BONE; PATHOLOGY; SECONDARY; SEVERITY OF ILLNESS INDEX;

ANIMALS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; SEVERITY OF ILLNESS INDEX;

EID: 84896402446     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.08.010     Document Type: Review

References (71)

1. S. Mukherjee et al. NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model J. Am. Chem. Soc. 130 2008 1264 1273 (Pubitemid 351171005)
2. R.G. Russell et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos. Int. 19 2008 733 759
3. F.H. Ebetino et al. The relationship between the chemistry and biological activity of the bisphosphonates Bone 49 2011 20 33
4. G.H. Nancollas et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 2006 617 627
5. A.J. Roelofs et al. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo J. Bone Miner. Res. 27 2012 835 847
6. R.G. Russell Bisphosphonates: the first 40 years Bone 49 2011 2 19
7. B. Pan et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE) J. Bone Miner. Res. 19 2004 147 154 (Pubitemid 41295147)
8. International Osteoporosis Foundation, www.iofbonehealth.org
9. R. van Balen et al. Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence Clin. Orthop. Relat. Res. 390 2001 232 243 (Pubitemid 32816797)
10. E.S. Siris et al. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008 J. Bone Miner. Res. 26 2011 3 11
11. H.G. Bone et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women N. Engl. J. Med. 350 2004 1189 1199 (Pubitemid 38339363)
12. R.R. Recker et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure J. Bone Miner. Res. 23 2008 6 16
13. D.M. Black et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial J. Am. Med. Assoc. 296 2006 2927 2938 (Pubitemid 46021497)
14. S. Silverman, and C. Christiansen Individualizing osteoporosis therapy Osteoporos. Int. 23 2012 797 809
15. R. Coleman The use of bisphosphonates in cancer treatment Ann. N. Y. Acad. Sci. 1218 2011 3 14
16. H.L. Neville-Webbe et al. Potential anticancer properties of bisphosphonates Semin. Oncol. 37 Suppl 1 2010 S53 S65
17. B. Psaila, and D. Lyden The metastatic niche: adapting the foreign soil Nat. Rev. Cancer 9 2009 285 293
18. R.E. Coleman Bisphosphonates: clinical experience Oncologist 9 Suppl 4 2004 14 27 (Pubitemid 39363165)
19. A.M. Gallagher et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates J. Bone Miner. Res. 23 2008 1569 1575
20. K.F. Huybrechts et al. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 2006 922 928 (Pubitemid 44498580)
21. V. Rabenda et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos. Int. 19 2008 811 818
22. E.S. Siris et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin. Proc. 81 2006 1013 1022 (Pubitemid 44175011)
23. J.A. Cramer et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos. Int. 18 2007 1023 1031 (Pubitemid 47019996)
24. S. Khosla et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J. Bone Miner. Res. 22 2007 1479 1491 (Pubitemid 351229318)
25. S. Ruggiero et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer J. Oncol. Pract. 2 2006 7 14
26. K. Vahtsevanos et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J. Clin. Oncol. 27 2009 5356 5362
27. A. Bamias et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J. Clin. Oncol. 23 2005 8580 8587 (Pubitemid 46211499)
28. B.G. Durie et al. Osteonecrosis of the jaw and bisphosphonates N. Engl. J. Med. 353 2005 99 102 discussion 199-102
29. A.M. Cafro et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid Clin. Lymphoma Myeloma 8 2008 111 116 (Pubitemid 351775769)
30. M.H. Abu-Id et al. 'Bis-phossy jaws' - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw J. Craniomaxillofac. Surg. 36 2008 95 103
31. H.M. Weiss et al. Biodistribution and plasma protein binding of zoledronic acid Drug Metab. Dispos. 36 2008 2043 2049
32. A. Grosso et al. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions Br. J. Clin. Pharmacol. 66 2008 689 694
33. T. Van den Wyngaert et al. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer 19 2011 2035 2040
34. A. Neuprez et al. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab Osteoporos. Int. 2013 [Epub ahead of print]
35. F. Correia Vde et al. Cytotoxicity evaluation of sodium alendronate on cultured human periodontal ligament fibroblasts Dent. Traumatol. 22 2006 312 317
36. D. Ribatti et al. Clodronate inhibits angiogenesis in vitro and in vivo Oncol. Rep. 19 2008 1109 1112
37. M. Kos et al. Clinical comparison of patients with osteonecrosis of the jaws, with and without a history of bisphosphonates administration Int. J. Oral Maxillofac. Surg. 39 2010 1097 1102
38. I.R. Reid Osteonecrosis of the jaw: who gets it, and why? Bone 44 2009 4 10
39. B. Balla et al. New approach to analyse genetic and clinical data in bisphosphonate-induced osteonecrosis of the jaw Oral Dis. 18 2012 580 585
40. T. Hansen et al. Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis - a paradoxical observation? Virchows Arch. 449 2006 448 454 (Pubitemid 44451319)
41. S. Bisdas et al. Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients Clin. Radiol. 63 2008 71 77 (Pubitemid 350212865)
42. P. Fournier et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res. 62 2002 6538 6544 (Pubitemid 35364119)
43. J. Wood et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J. Pharmacol. Exp. Ther. 302 2002 1055 1061 (Pubitemid 34920226)
44. S.L. Ruggiero et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J. Oral Maxillofac. Surg. 62 2004 527 534 (Pubitemid 38542516)
45. R.E. Marx et al. Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment J. Oral Maxillofac. Surg. 63 2005 1567 1575 (Pubitemid 41525412)
46. A.S. Neviaser et al. Low-energy femoral shaft fractures associated with alendronate use J. Orthop. Trauma 22 2008 346 350 (Pubitemid 351630250)
47. B.A. Lenart et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study Osteoporos. Int. 20 2009 1353 1362
48. S.K. Goh et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution J. Bone Joint Surg. Br. 89 2007 349 353
49. R.N. Thompson et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals J. Bone Joint Surg. Br. 94 2012 385 390
50. M.E. Puhaindran et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates J. Bone Joint Surg. Am. 93 2011 1235 1242
51. D.M. Black et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N. Engl. J. Med. 362 2010 1761 1771
52. R. Rizzoli et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report Osteoporos. Int. 22 2011 373 390
53. S.Y. Kim et al. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort J. Bone Miner. Res. 26 2011 993 1001
54. M.P. Somford et al. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility J. Bone Miner. Res. 24 2009 1736 1740
55. T. Mashiba et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles Bone 28 2001 524 531 (Pubitemid 32416465)
56. C.V. Odvina et al. Severely suppressed bone turnover: a potential complication of alendronate therapy J. Clin. Endocrinol. Metab. 90 2005 1294 1301 (Pubitemid 40463979)
57. E. Verron et al. Calcium phosphate biomaterials as bone drug delivery systems: a review Drug Discov. Today 15 2010 547 552
58. E. Verron et al. Controlling the biological function of calcium phosphate bone substitutes with drugs Acta Biomater. 8 2012 3541 3551
59. E. Verron et al. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite Biomaterials 31 2010 7776 7784
60. E. Boanini et al. The effect of alendronate doped calcium phosphates on bone cells activity Bone 51 2012 944 952
61. E. Boanini et al. The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells in vitro Biomaterials 33 2012 722 730
62. J.D. Bobyn et al. Locally delivered bisphosphonate for enhancement of bone formation and implant fixation J. Bone Joint Surg. Am. 91 Suppl 6 2009 23 31
63. V.A. Stadelmann et al. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study Eur. Cell Mater. 16 2008 10 16
64. A.O. Hoff et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates J. Bone Miner. Res. 23 2008 826 836 (Pubitemid 351768801)
65. C. Walter et al. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients Cancer 115 2009 1631 1637
66. T. Boonyapakorn et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies Oral Oncol. 44 2008 857 869
67. E.P. Wang et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy J. Oral Maxillofac. Surg. 65 2007 1328 1331 (Pubitemid 46915477)
68. T. Fehm et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies Gynecol. Oncol. 112 2009 605 609
69. J.V. Bagan et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases J. Oral Pathol. Med. 34 2005 120 123
70. M. Pazianas et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics Clin. Ther. 29 2007 1548 1558 (Pubitemid 47500128)
71. M.C. Farrugia et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates Laryngoscope 116 2006 115 120 (Pubitemid 44383974)